SY-008

Suzhou Yabao Pharmaceutical R&D Co., Ltd. · Phase 1 active Small molecule

SY-008 is a novel small molecule in development by Suzhou Yabao Pharmaceutical R&D Co., Ltd. for the treatment of Type 2 Diabetes Mellitus. It has completed Phase 1 trials, demonstrating safety and tolerability in healthy subjects and patients. The drug's mechanism of action and potential benefits are under further investigation.

At a glance

Generic name	SY-008
Sponsor	Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SY-008 CI brief — competitive landscape report
SY-008 updates RSS · CI watch RSS
Suzhou Yabao Pharmaceutical R&D Co., Ltd. portfolio CI